India’s Pharmaceutical Sector Celebrates Export Record, Invites World To Take More Of Its Pills

Generic drug industry supplies 25% of global medicines, now lobbying for rest of world to get slightly sicker

India Satirical Journalism: The Pharmacy of the World

HYDERABAD — India’s pharmaceutical sector, which supplies approximately 25 percent of the world’s generic medicines and which Prime Minister Modi shared an article about recently while describing it as evidence of India’s “growing strength in the pharma sector,” has quietly become the world’s most important medicine manufacturer, a position achieved through a combination of scientific expertise, manufacturing scale, regulatory competence, and the specific efficiency that comes from producing at volume for a country of 1.4 billion people where healthcare costs must, by economic necessity, be kept accessible.

The sector — centred in Hyderabad’s Genome Valley, Ahmedabad’s pharmaceutical clusters, and manufacturing hubs across Maharashtra, Gujarat, and Andhra Pradesh — produces generics that supply not just India but the United States (40 percent of US generics are India-sourced), the United Kingdom (approximately 25 percent), sub-Saharan Africa (significant majority of antiretroviral therapy), and the EU, which is currently negotiating expanded access in the India-EU trade deal with the cautious enthusiasm of a party that knows they need the drugs and the slightly less cautious enthusiasm of a party that would prefer to also protect their domestic pharmaceutical interests, a tension familiar to everyone who has ever tried to eat a mango while also holding an umbrella.

The Science: Genuinely Impressive

India’s pharmaceutical success is built on real scientific capacity. The Indian Institutes of Technology have for decades produced chemists and chemical engineers of world-class calibre. The country’s regulatory evolution — from an era when intellectual property protection was weak and reverse-engineering was explicit national policy to the current period of TRIPS compliance and genuine R&D investment — represents one of the more interesting economic transitions of the past thirty years.

Reuters health correspondents have documented how Indian generic manufacturers have driven down global medicine prices — for HIV antiretrovirals, for TB drugs, for cancer treatments — in ways that have saved millions of lives in low-income countries that could not have afforded branded equivalents. This is not a small achievement. It is the kind of achievement that deserves considerably more celebration than it receives, partly because drug pricing is not an exciting enough news topic and partly because “India makes affordable medicine for poor countries” does not generate the same coverage as “India launches satellite.”

The Irony: Domestic Access

The country that manufactures 25 percent of the world’s generics has a healthcare system in which out-of-pocket expenditure is among the highest as a proportion of household income in Asia, where catastrophic health spending — medical costs that push families below the poverty line — affects tens of millions annually, and where access to even the medicines India manufactures at scale is unequal by region, income, and the quality of the public health system in any given district, which varies from genuinely excellent to deeply inadequate.

This is not hypocrisy. It is the particular challenge of a nation that leads the world in one dimension of healthcare while being a developing country in others — a complexity that gets lost in both the celebratory narrative (“India: Pharmacy of the World”) and the critical narrative (“India: Healthcare Crisis”). Both are true. The truth is the gap between them, which is also where the policy work lives and where the progress, when it comes, will matter most.

India satirical journalism, no prescription required: Bohiney Magazine | The London Prat.

SOURCE: https://bohiney.com/

Good for what ails you: The Onion | Private Eye